Associated Papers
Mutational profiling using liquid biopsy to guide targeted therapy in patients with metastatic cancer.
Mazouji O et al.
Scientific Reports, 2025
40169620 (PubMed )
Supplement: 41598_2025_88094_MOESM2_ESM.xlsx › Feuil1
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
38713862 (PubMed )
Supplement: baae031_supp.zip › suppl_data › Database_Orlic_Milacic_Reactome_of_Disease_Variants_SupplementaryTable1.docx
Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Zhou Y et al.
Journal of Medicinal Chemistry, 2022
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
34058070 (PubMed )
Supplement: MOL2-15-2363-s001.docx
Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools.
Garcia J et al.
Scientific Reports, 2021
34031447 (PubMed )
Supplement: 41598_2021_89592_MOESM1_ESM.xlsx › Supplementary_Table_S3
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets.
Park HY et al.
Human Pathology, 2019
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.
Guan J et al.
Oncotarget, 2017
Select a paper to view details